Transaction in Own Shares

Summary by AI BETAClose X

CVS Group plc has purchased 202,164 ordinary shares at prices ranging from 1,227.00 pence to 1,250.00 pence, with a volume-weighted average price of 1,238.03 pence per share, as part of its ongoing share buyback programme. These shares will be cancelled, reducing the total number of ordinary shares in issue to 69,542,776. Since the programme began, CVS has repurchased 614,408 shares at a weighted average price of 1,245.32 pence.

Disclaimer*

CVS Group plc
15 June 2026
 

 15 June 2026
 

 CVS GROUP plc
 ("CVS" or the "Company" and, together with its subsidiaries, the "Group")
 Transaction in Own Shares

CVS announces that it purchased the following number of its ordinary shares of 0.2 pence each ("Ordinary Shares") from Peel Hunt LLP ("Peel Hunt"), in accordance with the terms of the share buyback programme announced on 26 May 2026 (the "Share Buyback Programme").

Date of purchases:

08/06/2026 - 12/06/2026

Aggregate number of Ordinary Shares purchased:

202,164

Lowest price paid per share (GBp):

1,227.00

Highest price paid per share (GBp):

1,250.00

Volume weighted average price paid per share (GBp):

1,238.03

CVS intends to cancel all of the purchased Ordinary Shares.

Following settlement of the above purchases and cancellation of the Ordinary Shares purchased, CVS will have 69,542,776 Ordinary Shares in issue and holds no Ordinary Shares in treasury.

The total number of voting rights in CVS is therefore 69,542,776 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, CVS under the Financial Conduct Authority's Disclosure and Transparency Rules.

Since the commencement of the Share Buyback Programme, the Company has repurchased 614,408 Ordinary Shares in aggregate at a weighted average price of 1,245.32 pence per share.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), as it forms part of Retained EU Law as defined in the European Union (Withdrawal) Act 2018, a full breakdown of the individual trades made by Peel Hunt as part of the Share Buyback Programme is attached to this announcement: http://www.rns-pdf.londonstockexchange.com/rns/1946I_1-2026-6-12.pdf

 Contacts

CVS Group plc

via FGS Global

Richard Fairman, Chief Executive Officer

 

Robin Alfonso, Chief Financial Officer

 

Paul Higgs, Chief Veterinary Officer

 

Charlotte Page, Head of Investor Relations

 

 

 

FGS Global

 +44 (0)207 251 3801

Faeth Birch

 

Charlie Chichester

 

 

About CVS Group plc (www.cvsukltd.co.uk)

CVS Group is a leading provider of veterinary services, operating in the UK and Australia, listed on the Main Market of the London Stock Exchange. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

The Group operates over 475 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").

The Group employs 9,000 personnel, including 2,500 veterinary surgeons and 3,300 nurses.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

CVS Group (CVSG)
UK 100

Latest directors dealings